Dexcom, Inc. DXCM
Dexcom's blow-out growth is a sugar high — driven by hidden price hikes and sensor stockpiling — and Abbott's cheap Libre 2 will commoditize CGMs, taking DXCM down 45-60% to $65-$85.
Thesis
Spruce Point argues Dexcom is a one-product company whose recent revenue acceleration is misleadingly inflated by an effective ~56% sensor price increase and channel stockpiling of legacy G4/G5 sensors ahead of the G6 launch — not by underlying patient growth, which management conveniently stopped disclosing in FY18. Abbott's forthcoming Libre 2 will be technologically comparable to the G6 but priced at an ~80% discount, with Abbott already capturing >70% of incremental U.S. T1 share and >95% of T2 share. Dexcom has no down-market product to bridge the ~18-month gap to a delayed G7, leaving its T1 runway exhausted (only 0.3M patients left) and the T2 market untouchable at G-Series prices. At a 57% EV/Sales premium to peers and a multiple that has stalled despite revenue beats, Spruce Point sees 45-60% near-term downside to $65-$85 per share.
SCQA
Dexcom is the dominant stand-alone CGM maker, whose G6 has been considered the gold standard for Type 1 diabetics, and whose stock has run up sharply on the bull narrative of expanding CGM adoption.
Abbott's Libre 2 closes the technology gap at an ~80% price discount, while Dexcom's recent growth was actually driven by hidden price hikes and legacy-sensor stockpiling — and management quietly stopped disclosing patient base figures in FY18.
Sell DXCM. The Street is misinterpreting transmitter-vs-sensor sales decoupling, ignoring Libre 2 risk, and applying aspirational multiples that should rerate to peer-level 5-6x EV/Sales as growth disappoints.
Spruce Point sees 45-60% near-term downside to $65-$85 per share based on FY20 revenue of $1.16-1.26B at a 5-6x multiple, with even more significant longer-term tail risk if Dexcom fails to compete in T2.
The three reasons
- 1
Abbott's cheaper Libre 2 closes the technology gap and is priced ~80% below Dexcom's G6
- 2
Recent sales growth driven by stealth price hikes and G4/G5 sensor stockpiling, not patient growth
- 3
DXCM trades at 57% EV/Sales premium to peers despite imminent commoditization risk
Primary demands
- Sell DXCM shares (Strong Sell rating)
- Management should resume disclosing patient base growth figures it stopped reporting in FY18
KPIs cited
Pattern membership
Precedents cited
- Weis Markets short (Sep 2018)
- Maxar Technologies short (Aug 2018)
- Bazaarvoice short (May 2012)
Composition what's on the 83 slides
Slide gallery ·
Notes
Memorable 'Sugar High' framing on cover (with cheeky 'I Love Ben' tattoo and CGM stock-alert visual). Strong SCQA structure: bull interpretation vs Spruce Point interpretation panels (p.6) deliver clear before/after framing. Page 70 is a textbook CEO-quote-contradiction slide showing four years of JP Morgan Healthcare Conference quotes where management proudly disclosed patient base, then suddenly stopped. The villain is institutional (management writ large) rather than a single named CEO; CFO Quentin Blackford appears in a quoted analyst note. Stake size not disclosed (typical of short reports — Spruce Point only states they hold short positions in the disclaimer).